Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC

NCT05822752 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05822752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05822752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 21, 2023
Completion date
November 30, 2026
Enrollment
130 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma